Novel GLP-1 analog injection reduced weight for Chinese adults with overweight, obesity
Click Here to Manage Email Alerts
Key takeaways:
- Biweekly and weekly GLP-1 analog injections resulted in robust body weight reductions after 30 weeks.
- The injection also improved cardiometabolic parameters for adults with overweight or obesity.
SAN ANTONIO — For Chinese adults with overweight or obesity, GLP-1 analog injections were safe and well tolerated, demonstrating robust body weight reductions and improved cardiometabolic parameters, researchers reported.
At ObesityWeek, Linong Ji, MD, professor and director of the department of endocrinology and metabolism at Peking University People’s Hospital in Beijing, and colleagues presented data from a phase 2b trial that evaluated the effect of GZR18 (Gan & Lee Pharmaceuticals) in 286 Chinese adults with a BMI of at least 28 kg/m2 or a BMI of at least 24 kg/m2 with at least one obesity-related comorbidity. Participants were randomly assigned to doses up to 12 mg biweekly (n = 44), doses up to 18 mg biweekly (n = 49), doses up to 24 mg biweekly (n = 45), doses up to 48 mg biweekly (n = 46), doses up to 24 mg once weekly (n = 45) or placebo (n = 57) for 30 weeks with 4 weeks titration until maximum dose.
The primary outcome was the body weight percentage change from baseline to 30 weeks. Secondary outcomes included body weight reductions of 5%, 10%, 15% and 20%, weight in kilograms, BMI, waist and hip circumference and cardiometabolic parameters.
All treatment groups demonstrated superior percentage changes in body weight from baseline to 30 weeks compared with placebo, with –10.2% difference for 12 mg biweekly, –12.2% for 18 mg biweekly, –13.3% for 24 mg biweekly, –16.3% for 48 mg biweekly and –16.8% for 24 mg weekly (P < .001 for all).
In addition, 38% of the 48 mg biweekly group and 40% of the 24 mg weekly group achieved body weight reductions higher than 20% with GZR18 injections. The 48 mg biweekly or 24 mg weekly groups also demonstrated significant reductions in weight in kilograms (–16.5 kg and –16.7 kg, respectively), BMI (–5.8 cm/kg2 and –5.7 cm/kg2, respectively), waist circumference (–14.2 cm and –13.7 cm, respectively) and hip circumference (–10.6 cm and –9.8 cm, respectively).
All GRZ18 groups achieved body weight reductions of 5%, 10%, 15% and 20% at a greater rate than the placebo group, according to the researchers.
Researchers also observed robust reductions in systolic and diastolic blood pressure, fasting blood glucose and HbA1c, and improvements in lipid parameters.
Safety was similar to incretin-based therapies, with gastrointestinal reactions the most commonly reported adverse event. Researchers observed no serious adverse events related to GZR18 injections.
“GZR18 demonstrated robust body weight reductions in overweight or obese adults in the Chinese population when administrated in a weekly or biweekly fashion with no significant difference between 48 mg biweekly and 24 mg weekly administration. GZR18 improved cardiometabolic parameters for people, even with obesity or overweight and GZR18 was basically safe and very well tolerated,” Ji said during the presentation. “This result supports the phase 3 clinical confirmatory studies to further validate the safety of GZR18.”
Collapse
Ji L, et al. Oral-106. Presented at: ObesityWeek; Nov. 3-6, 2024; San Antonio.
Read more about
Click Here to Manage Email Alerts